Home/Iterum Therapeutics/Corey N. Fishman
CN

Corey N. Fishman

Chief Executive Officer

Iterum Therapeutics

Iterum Therapeutics Pipeline

DrugIndicationPhase
ORLYNVAH™ (sulopenem)Uncomplicated Urinary Tract Infection (uUTI)Approved